<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>在有争议的辩论之后，自2003年以来，FDA批准了先阿尔茨海默氏药物 
				After contentious debate, FDA approves first Alzheimer’s drug since 2003			</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">
				After contentious debate, FDA approves first Alzheimer’s drug since 2003			<br/>在有争议的辩论之后，自2003年以来，FDA批准了先阿尔茨海默氏药物 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-06-08 05:25:13</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/6/a624074de2ad719e19cc05d13c198bf0.png"><img src="http://img2.diglog.com/img/2021/6/a624074de2ad719e19cc05d13c198bf0.png" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>Aducanumab, which will be marketed as Aduhelm, is the first novel Alzheimer’s treatment to be approved since 2003, the FDA noted in a press release. Aducanumab is also the first novel treatment designed to address   one of several  proposed underlying causes of Alzheimer’s: the buildup of beta-amyloid plaques in the brain that disrupt the communication of neurons.</p><p>阿杜纳姆（Aducanumab）将被销售为Aduhelm，是自2003年自2003年以来批准的第一个新的Alzheimer治疗，FDA在新闻稿中注明。阿杜纳姆也是第一个新的治疗方法，旨在解决阿尔茨海默氏症的几种提出的潜在原因之一：扰乱神经元通信的大脑中β-淀粉样斑块的累积。</p><p> Critically, the drug received a conditional form of FDA approval called the ‘ Accelerated Approval Program.’ The accelerated approval pathway is designed to provide early access to drugs for serious conditions if they address markers of disease – even when the FDA has misgivings about the overall results of clinical trials. Because of this, Biogen will still have to conduct a post-approval confirmatory trial of aducanumab.</p><p> 批判性地，该药物接受了一个有条件形式的FDA批准，称为“加速审批计划”。加速批准途径旨在提供早期对疾病标志物的严重条件的药物，即使FDA有关于整体的疑虑临床试验结果。因此，生物原性仍然必须进行阿杜纳布的批准后试验。</p><p>  “ If the drug does not work as intended, we can take steps to remove it from the market. But hopefully, we will see further evidence of benefit in the clinical trial and as greater numbers of people receive Aduhelm,” the FDA statement   reads.</p><p>  “如果药物不按预期工作，我们可以采取措施将其从市场上删除。但希望，我们将在临床试验中看到进一步的益处证据，并随着更多人收到Aduhelm，“FDA声明读。</p><p> TechCrunch has contacted Biogen for comment on the upcoming confirmatory trial, and will update this story with Biogen’s response.</p><p> TechCrunch已联系Biogen关于即将到来的确认试验评论，并将用生物原性的回应更新本故事。</p><p> The use of the accelerated approval pathway is clearly intended to address lingering controversies that have plagued aducanumab in the months leading up to the FDA’s ruling.</p><p> 加速批准途径的使用明显旨在解决在通往FDA裁决的几个月内困扰血管损伤的挥之不去的争论。</p><p> In early-stage trials, there were promising signs that aducanumab might slow cognitive decline, a major Alzheimer’s symptom. In a 2016   trial  published in the journal   Nature , 125 patients with mild or moderate Alzheimer’s who received monthly infusions of the drug saw levels of plaques decrease, as did symptoms of cognitive decline.</p><p> 在早期试验中，有前景的迹象表明，阿杜曼亚可患认知率降低，令人瞩目的症状，这是一个主要的阿尔茨海默氏症。在2016年审判中发表于自然杂志，125例温和或中度阿尔茨海默患者接受了每月药物的药物锯的斑块斑块减少，尽管认知下降的症状。</p><p> The decline of the plaques in the brain were   “robust and unquestionable”  as one   Lancet Neurology  paper puts it, but the clinical findings were more modest – it wasn’t clear exactly how much people’s cognitive ability benefitted from the treatment.</p><p> 随着一个刺血针神经内容纸张，大脑中的斑块的衰落是“坚固且无能的”，但临床发现更为适度 - 这并不清楚有多少人从治疗中受益的能力。 </p><p> These early trials eventually led the FDA to allow the drug to skip phase 2 clinical trials, which are designed to identify dosages of the drug, and proceed directly to phase 3 clinical trials. This move was   criticized  by some physicians.</p><p>这些早期试验最终导致FDA允许药物跳过阶段2临床试验，该试验旨在鉴定药物的剂量，并直接进行第3期临床试验。这一举措受到一些医生的批评。</p><p> Those phase 3 clinical trials, called   ENGAGE  and   EMERGE , have become the center of tension. Both trials tested monthly intravenous injections of the drug on about 1600 patients with early Alzheimer’s. In 2019, both trials were   halted  because the drug didn’t appear to be slowing cognitive decline, the primary endpoint of the trials.</p><p> 这些第3阶段临床试验，称为接合和出现，已成为张力的中心。两项试验两项试验在早期的阿尔茨海默氏症患者上测试每月静脉注射药物。 2019年，两项试验都停止了，因为药物似乎没有缓慢的认知下降，试验的主要终点。</p><p> Additional data analyzed in late 2019 from the EMERGE trial suggested that the drug was linked with a   23 percent less  cognitive decline, compared to a placebo. There were side effects: namely swelling and inflammation of the brain. This was seen in about   40 percent  of Phase 3 trial participants, though most were symptomatic and most of those with symptoms (headache, nausea, visual disturbances) resolved after 4-16 weeks.</p><p> 与安慰剂相比，2019年延迟分析的额外数据表明该药物与认知下降减少23％。有副作用：即大脑的肿胀和炎症。这是在3阶段3阶段试验参与者的40％中看到的，尽管大多数是症状和大多数有症状（头痛，恶心，视觉干扰）在4-16周后解决的那些。</p><p> Still, even the new data wasn’t enough to convince an independent FDA advisory committee, who, in November 2020   did not endorse  approval of the drug.</p><p> 尽管如此，即使是新数据也不足以说服一个独立的FDA咨询委员会，世卫组织于2020年11月2020年，没有认可药物批准。</p><p> On Monday, The FDA,   argued  that the drug’s effects on   beta-amyloid plaques  were strong enough to suggest that benefit outweighed the risk. Critically, the FDA did not comment on the   strength of clinical outcomes  – in short, the agency   is basing this approval  on the drug’s ability to address beta-amyloid plaques, not how well each patient cognitive function responds to the drug. The followup study will need to address that outcome directly.</p><p> 在FDA周一，FDA认为，药物对β-淀粉样蛋白斑块的影响足以推动益处超过风险。批判性地，FDA没有评论临床结果的实力 - 简而言之，原子能机构基于这种批准对药物解决β-淀粉样斑块的能力，而不是每种患者认知功能对药物的反应程度。后续研究需要直接解决这一结果。</p><p> Still, about   6 million people  have Alzheimer’s in the US, and patient organizations have rallied in response to this drug.   The Alzheimer’s Association  has hailed the drug as a “victory for people living with Alzheimer’s.”</p><p> 仍然，大约600万人在美国拥有阿尔茨海默，患者组织因这种药物而集结。阿尔茨海默氏症的协会称为药物作为“与阿尔茨海默氏症的人的胜利”。</p><p> Ahead of the FDA’s decision on Monday, it was clear that, should aducanumab be approved, it would soon become a “blockbuster drug.” The financial picture around the drug seems to support that idea.</p><p> 在FDA周一的决定之后，很明显，应该批准，应该很快成为“大象药的药物”。药物周围的金融照片似乎支持这种想法。 </p><p> Trading of Biogen shares were initially halted, but have since   jumped  40 percent today, following the announcement. Shares of Eisai Co. Ltd, a Japanese company working with Biogen   jumped over 46 percent  in the first three hours following the FDA’s approval.</p><p>宣布之后，生物股的交易最初被停止，但自今天的涨幅为40％。 Eisai Co. Ltd的股票，日本公司在FDA批准后的前三个小时内与Biogen一起使用超过46％。</p><p> Certainly, Biogen was banking on this approval as a long-term strategy. In an April 2021,   earnings presentation , the company estimated that there were 600 sites ready to launch the treatment post-approval. Biogen has also submitted marketing authorization applications for aducanumab in Brazil, Canada, Switzerland and Australia. On June 7, the company announced that a year’s supply of the drug would   cost $56,000 .</p><p> 当然，Biogen是这项批准的银行业作为一个长期战略。在2021年4月，盈利介绍，公司估计有600个网站准备发动批准后的待遇。 Biogen还向巴西，加拿大，瑞士和澳大利亚的Aducanumab提交了营销授权申请。 6月7日，该公司宣布，一年的药物供应量将耗资56,000美元。</p><p> In the wider world of Alzheimer’s drugs, it’s possible other companies may see this approval as proof-of-concept for other drugs targeting beta amyloid plaques.</p><p> 在更广泛的Alzheimer毒品世界中，其他公司可能会将这一批准视为靶向β淀粉样斑块的其他药物的概念。</p><p> In an   editorial  that accompanied the 2016   Nature  paper on aducanumab, Eric Reiman, executive director of Banner Alzheimer’s Institute, argued that scientific confirmation that beta-amyloid-targeted treatment slows cognitive decline would be a “game changer.” The aducanumab trials have been likened to a test of this idea. Speaking to   The Financial Times,  Howard Filit, founding executive director of the Alzheimer’s Drug Discovery Foundation,   called  aducanumab “the first rigorous test of the beta-amyloid hypothesis.”</p><p> 在Aducanumab的2016年自然论文附带的编辑器中，横幅阿尔茨海默尔研究所的执行董事Eric Reiman，认为β-淀粉样蛋白靶向治疗的科学确认减缓认知下降将是“游戏更换者”。阿杜曼巴布试验被比作了这个想法的考验。谈到金融时报，霍华德申请，阿尔茨海默氏症的药物发现基金会的创始执行董事，称为Aducanumab“β-淀粉样蛋白假设的第一次严格测试。”</p><p> In that sense, conditional approval may indicate that the FDA is sympathetic to this form of Alzheimer’s treatment.</p><p> 从这种意义上讲，有条件的批准可能表明FDA对这种形式的阿尔茨海默治疗是同情的。</p><p> There’s   at least one  more beta-amyloid targeted drug from a major drugmaker (Eli Lilly) clinical trials. We may see some more of them emerge soon, provided that Biogen’s confirmatory study of aducanumab doesn’t prompt the FDA to withdraw approval.</p><p> 来自主要药物制造商（Eli Lilly）的临床试验至少还有一种更多的β-淀粉样蛋白靶向药物。我们可能会很快看到更多的人，只要生物原性对亚达曼巴布的确认研究没有提示FDA撤销批准。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://techcrunch.com/2021/06/07/after-contentious-debate-fda-approves-first-alzheimers-drug-since-2003/">https://techcrunch.com/2021/06/07/after-contentious-debate-fda-approves-first-alzheimers-drug-since-2003/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/争议/">#争议</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/debate/">#debate</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/药物/">#药物</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>